Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data
Daridorexant (dari), as the first dual orexin receptor antagonist (DORA) marketed in Europe, offers a novel therapeutic approach to insomnia. However, data regarding its real-world safety are scarce. Thus, this study was aimed at assessing its safety profile using a large-scale pharmacovigilance dat...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2024-03-01
|
| Col·lecció: | Pharmaceuticals |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1424-8247/17/3/342 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|